

Leuchtturm Omics, Genomics, und Liquid Biopsy (LT Omics)

Our overarching aims are:

1) developing cutting-edge methods with focus on proteogenomics and liquid biopsy,

- 2) improving patient care with MTBs as core element and
- 3) setting up a decentralized core facility for BZKF members.

Sprecher: Prof. Dr. Rainer Claus

Concept & Milestones

Concept

The LT Omics is interlinked with BZKF Arbeitsgruppen (AG), *Studiengruppen* (SG) and other LTs. This creates a unique setup for establishing and providing cutting--edge methods. Thus, the LT Omics works as hub for translational research - an effective transition from oncological research to patient care.

Milestone I Use-case project I: MTB 2.0 Novel functional methods are guiding therapy decisions of MTB clinicians in rare cancers (use-case salivary gland cancer).

Milestone II Assessing minimal residual disease (MRD) and characterizing circulating multiple myeloma cells (CMMC).

Use-case project II: CMMC BZKF decentralized core facility: Bundle methods&expertise, provide standards&manuals at one place accessible for all BZKF members to facilitate collaborative projects.

Concept & Milestones

Milestone III



Long-term goals

- Conduction of use-case clinical trials and **>>** refinement of methods
- Further integration of suitable methods into and **》** setting up a next generation of MTBs in Bavaria
- Transfer developed techniques and workflows to **》** further rare and difficult-to-treat cancers

Expansion of BZKF decentralized core facility 》

Authors (in alphabetical order): Barbara Alberter, Andreas Baur, Rainer Claus, Markus Eckstein, Fulvia Ferrazzi, Nina Fischer, Martin Fromm, Arne Gessner, Christoph Irlbeck, Frederick Klauschen, Christoph Klein, Cäcilia Köstler, Bernhard Küster, Florian Lüke, Bernhard Polzer, Roland Rad, Maria Reinecke, Andreas Rosenwald, Marius Schliemann, Annika Schneider, Steffi Treitschke, Kristian Unger, Jan van Deun, Christian Werno, Christof Winter.

Gefördert durch

